Additionally, low-dose administration of WIN has been shown to increase CB1R activity in the cortex of a rat model of cholinergic degeneration, resulting in improved cognitive performance [78], whereas in a rat model of cerebral ischemia, WIN treatment significantly increased CB1R protein levels in the hippocampus [79]. This evidence concerns the gene CNR1 and brain ischemia.